Drug Trial News

RSS

New drug candidate found to be highly effective in treating rare sight-threatening eye infection

A drug candidate, based on pioneering UCL and Moorfields Eye Hospital research and currently under development by SIFI S.p.A., has been found to be highly effective in treating a rare sight-threatening eye infection in a new international clinical trial.

26 Oct 2023

Dato-DXd improves progression-free survival in patients with metastatic non-squamous NSCLC

Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small cell lung cancer, an improvement that was primarily driven by patients with non-squamous tumors.

26 Oct 2023

Global clinical trial provides new evidence on simvastatin and vitamin C for COVID-19

The Global Coalition for Adaptive Research (GCAR) in collaboration with the University of Pittsburgh and UPMC, on behalf of the REMAP-CAP Investigator Network, announce clinical trial results examining the use of vitamin C and simvastatin to treat severely ill patients with COVID-19.

25 Oct 2023

New course of treatment with existing drugs for cervical cancer reduces risk of death by 35%

A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH.

25 Oct 2023

HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

24 Oct 2023

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.

24 Oct 2023

Neoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.

24 Oct 2023

Chemotherapy plus immunotherapy improves survival in patients with metastatic urothelial cancer

A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer.

22 Oct 2023

Perioperative immunotherapy improves event-free survival in resectable early-stage lung cancer

Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC).

22 Oct 2023

Short course of induction chemotherapy can reduce cervical cancer relapse and death by 35%

The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre, assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could reduce the rate of relapse and death among patients with locally advanced cervical cancer.

22 Oct 2023

Dual-action drug produces shows promising results in neuroendocrine tumor trial

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.

22 Oct 2023

Everolimus after surgery may benefit patients with very-high-risk clear cell renal cell carcinoma

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.

22 Oct 2023

Clinical study evaluates safety and efficacy of methylone in patients with severe PTSD

Clerkenwell Health, the modern mental health company specializing in matching patients with cutting-edge psychiatry treatments, today announced that it is taking part in Transcend Therapeutics’ Phase 2 study evaluating the safety and efficacy of methylone in patients with severe PTSD.

20 Oct 2023

"Two-for-one" cancer immunotherapy more effective and at least as safe as standard treatments

A "two-for-one" cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial report today in the journal Nature Medicine.

19 Oct 2023

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks

New orally-administered GLP-1 receptor agonists danuglipron and orforglipron show promise in treating type 2 diabetes and obesity, according to a systematic review. While effective in glycemic control and weight reduction, these drugs come with gastrointestinal side effects that may lead to treatment discontinuation.

17 Oct 2023

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

In a groundbreaking 84-week-long study, researchers found that tirzepatide, a medication initially designed for treating type 2 diabetes, significantly bolstered weight loss in overweight and obese patients already on intensive lifestyle programs. While the drug showed promise in further reducing body weight and improving cardiometabolic factors, mild to moderate gastrointestinal side effects were the most common drawback.

16 Oct 2023

Widely available prescription drug can improve IBS symptoms

A cheap and widely available prescription drug can improve symptoms of irritable bowel syndrome in patients seen in GP surgeries, new research presented today at UEG Week 2023 has found.

16 Oct 2023

Two 'big gun' antibiotics may be safer for the kidneys than previously thought

Two 'big gun' antibiotics thought to cause kidney failure in ICU patients with a severe bacterial infection, especially when combined with another antibiotic, may be safer for the kidneys than previously reported, following a randomized trial led by Vanderbilt University Medical Center.

16 Oct 2023

Early intervention with sublingual immunotherapy may lead to remission of peanut allergy

A three-year clinical trial funded by the National Institutes of Health and Food Allergy Research and Education (FARE) has shown that the sublingual immunotherapy, or SLIT, is safe in peanut-allergic children ages 1 to 4, with a greater likelihood of desensitization and remission the earlier the treatment began.

13 Oct 2023

Moderna's updated COVID-19 vaccine for Autumn 2023 outperforms in cost and clinical impact

Moderna's updated mRNA-1273.815 COVID-19 vaccine shows promising results in reducing symptomatic cases, hospitalizations, and deaths in high-risk and older adults in Germany. The study finds the vaccine to be more cost-effective and clinically beneficial than both no vaccination and Pfizer's XBB.1.5 BNT162b2 vaccine.

12 Oct 2023

Previous
1
...
4
5
6
7
8
9
10
...
1135
Next

Drug Trial News

New drug candidate found to be highly effective in treating rare sight-threatening eye infection

Dato-DXd improves progression-free survival in patients with metastatic non-squamous NSCLC

Global clinical trial provides new evidence on simvastatin and vitamin C for COVID-19

New course of treatment with existing drugs for cervical cancer reduces risk of death by 35%

HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

Neoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma

Chemotherapy plus immunotherapy improves survival in patients with metastatic urothelial cancer

Perioperative immunotherapy improves event-free survival in resectable early-stage lung cancer

Short course of induction chemotherapy can reduce cervical cancer relapse and death by 35%

Dual-action drug produces shows promising results in neuroendocrine tumor trial

Everolimus after surgery may benefit patients with very-high-risk clear cell renal cell carcinoma

Clinical study evaluates safety and efficacy of methylone in patients with severe PTSD

"Two-for-one" cancer immunotherapy more effective and at least as safe as standard treatments

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

Widely available prescription drug can improve IBS symptoms

Two 'big gun' antibiotics may be safer for the kidneys than previously thought

Early intervention with sublingual immunotherapy may lead to remission of peanut allergy

Moderna's updated COVID-19 vaccine for Autumn 2023 outperforms in cost and clinical impact

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News